Cotadutide (MEDI0382): Risks & Legal Status

Critical Safety Information#

Cotadutide (MEDI0382) was a discontinued investigational compound that was never approved by any regulatory agency. AstraZeneca terminated its clinical development in April 2023 as a strategic decision to advance the weekly successor compound AZD9550. The discontinuation was not driven by safety concerns.

Program Discontinuation#

AstraZeneca's decision to discontinue cotadutide was driven by competitive positioning:

• Daily dosing limitation: In a market where weekly GLP-1 agonists are standard, cotadutide's daily dosing was a significant competitive disadvantage
• Next-generation compound: AZD9550 was designed as a weekly GLP-1/glucagon dual agonist to address this limitation
• Resource allocation: AstraZeneca chose to concentrate development resources on the more competitive weekly molecule

Risk Categories#

Investigational Status Risk#

Cotadutide never underwent phase 3 evaluation or regulatory review. Phase 2 data, while promising, do not provide the level of evidence required for clinical decision-making. The safety database is limited to approximately 834 patients in the largest trial with maximum 54-week exposure.

Gastrointestinal Risk#

GI adverse events were the most common safety finding, with nausea in 35% and vomiting in 17% of treated patients. While these rates are within the range observed for GLP-1-based therapies, they represent a notable treatment burden.

Glucagon-Related Risk#

The theoretical risks of chronic glucagon receptor co-agonism include:

• Hyperglycemia (mitigated by GLP-1-biased selectivity)
• Increased hepatic glucose output
• Ketogenesis
• Unknown long-term hepatic effects

These concerns were not realized as clinically significant problems in the phase 2 data, but the limited duration and sample size preclude definitive safety conclusions.

Regulatory Status#

Cotadutide is classified as a discontinued investigational compound in all jurisdictions. It is not available for clinical use, research purchase, or any other purpose. The GLP-1/glucagon dual agonist concept continues to be explored by other pharmaceutical companies with different molecules.

Risk Assessment Context#

Cotadutide (MEDI0382) belongs to the Metabolic category of research peptides. Risk assessment for Cotadutide (MEDI0382) should consider both the compound-specific risks identified in clinical research and the broader regulatory environment. Researchers and healthcare providers should evaluate these risks in the context of the specific patient population and therapeutic indication.

Risk Categories#

The following risk categories have been identified for Cotadutide (MEDI0382) based on available evidence and regulatory assessments:

Investigational Status#

Cotadutide was an investigational compound that never received regulatory approval from any agency. Clinical development was discontinued by AstraZeneca in April 2023. The drug is not available for clinical use, research purchase, or any other purpose.

Gastrointestinal Adverse Events#

Nausea (35%) and vomiting (17%) were the most common adverse events in phase 2b trials. While rates decreased over time, they exceeded those of some approved GLP-1 agonists.

Glucagon-Related Metabolic Effects#

The glucagon receptor agonism component carries theoretical risks including hyperglycemia and ketogenesis. While the GLP-1-biased selectivity of cotadutide was designed to mitigate these, long-term effects of chronic glucagon receptor co-agonism were not assessed.

Limited Long-Term Safety Data#

Maximum treatment duration in clinical trials was 54 weeks. No long-term safety data beyond this period were obtained. The chronic effects of dual GLP-1/glucagon agonism on hepatic, cardiovascular, and other organ systems remain uncertain.

Regulatory Status by Jurisdiction#

The regulatory and legal status of Cotadutide (MEDI0382) varies by country and jurisdiction. Researchers should verify current regulations before acquiring or using this compound.

Regulatory classifications can change. Researchers are responsible for complying with all applicable laws and regulations in their jurisdiction.

Important Warnings#

The following warnings apply to Cotadutide (MEDI0382):

• DEVELOPMENT DISCONTINUED: AstraZeneca discontinued cotadutide (MEDI0382) development in April 2023 in favor of the weekly successor AZD9550. The decision was strategic, not safety-driven.
• NEVER APPROVED: Cotadutide was never approved by any regulatory authority worldwide. It is not available for clinical use, pharmacy dispensing, or research purchase.
• INVESTIGATIONAL ONLY: All efficacy and safety data are from phase 2 clinical trials. Phase 3 confirmatory data were never generated.
• DUAL AGONISM RISKS: The combination of GLP-1 and glucagon receptor agonism carries theoretical metabolic risks that may not be fully characterized by the available clinical data.

These warnings are based on available preclinical and clinical data. The absence of a warning does not indicate safety. Consult qualified professionals before making any decisions regarding peptide research.

Related Reading#

• Cotadutide (MEDI0382) overview and research guide
• Cotadutide (MEDI0382) side effects profile
• Cotadutide (MEDI0382) research evidence